leukaemia. Lymphoid leukaemia, Myeloid leukaemia
Conditions
Interventions
Intervention 1: Intervention group:
administration of 50 mg zinc sulphate capsule, three times daily for 14 days from the first day of chemotherapy. Intervention 2: Control group:
administration of pl
Prevention
Intervention group:
administration of 50 mg zinc sulphate capsule, three times daily for 14 days from the first day of chemotherapy.
Control group:
administration of placebo capsules, three times daily for 14 days from the first day of chemotherapy.
Sponsors
Vice chancellor for research affairs of Shiraz University of Medical Science
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria of the study were leukemia patients with 18 years old or above, under chemotherapy, be alerted and oriented, and able to swallow capsule and did not show the mucositis symptoms such as ulcers, erythema, oedema, painful and dysphasia.The patients with any ulcer in their mouth, pregnant and lactating women, individuals under head and neck radiotherapy and patients who had the allergic to zinc were excluded from the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mucositis. Timepoint: Fourth, seventh,14th day from starting chemotherapy. Method of measurement: JP Donnelly and Colleagues questionnaire, and World Health Organization mucositis scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoume Rambod
Shiraz University of Medical Science
Outcome results
None listed